Opc    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病4

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04265027
(ClinicalTrials.gov)
February 20, 20187/2/2020Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)An Open Label, Randomised, Two Period, Crossover Study to Assess Bioavailability, Bioequivalence and S COMT Activity Between Two Active Pharmaceutical Ingredient Sources of Opicapone at Two Different Dosage Strengths (50 mg and 25 mg) After Single and Multiple Dose Administrations Under Fasting Conditions in Healthy Volunteers.Parkinson DiseaseDrug: 50 mg BIA 9 1067;Drug: 25 mg BIA9 1067;Drug: 50 mg Ongentys;Drug: 25 mg OngentysBial - Portela C S.A.NULLCompleted18 Years55 YearsAll72Phase 1United Kingdom
2NCT03116295
(ClinicalTrials.gov)
June 20, 201712/4/2017Bioavailability and Bioequivalence Study of Two Different Sources of OpicaponeA Comparative, Randomized, Open-label, Fasted, Single-dose, 2-way Crossover Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone in Healthy SubjectsParkinson DiseaseDrug: Opicapone (OPC)Bial - Portela C S.A.NULLCompleted18 Years55 YearsAll56Phase 1Germany
3NCT03116308
(ClinicalTrials.gov)
November 21, 201412/4/2017Effect of Food on OpicaponeEffect of Food on Opicapone Bioavailability and Pharmacodynamics in Healthy SubjectsParkinson DiseaseDrug: Opicapone (OPC)Bial - Portela C S.A.NULLCompleted18 Years45 YearsAll28Phase 1NULL
4NCT02169427
(ClinicalTrials.gov)
March 201124/1/2012An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and MetabolitesAn Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites Following a Single Dose Oral AdministrationParkinson's Disease (PD)Drug: OPCBial - Portela C S.A.NULLCompleted18 Years55 YearsMale6Phase 1Netherlands